Specifically, focused attention (PoA) showed a clinically meaningful decline of 59 ms over 6 months in very mildly impaired Alzheimer's disease patients (MMSE >26) taking cholinesterase inhibitors 48. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.